Boceprevir dosing for late responders and null responders: The role of bridging data between treatment‐naïve and ‐experienced subjects - Florian, Jeffry; Jadhav, Pravin R.; Amur, Shashi; Ayala, Ruben; Harrington, Patrick; Mishra, Poonam; O'Rear, Jules; Pacanowski, Michael; Robertson, Sarah; Singer, Mary; Soon, Greg; Zeng, Wen; et al. (Hepatology (Baltimore, Md.), 2013)
Keywords: Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Clinical Trials, Phase III as Topic - methods; Drug Approval - methods; Drug Monitoring - methods; Drug Resistance, Viral; Drug Therapy, Combination - standards; Evidence-Based Medicine - methods; Hepatitis C, Chronic - drug therapy; Hepatology; Humans; Interferon-alpha - therapeutic use; Proline - administration & dosage; Proline - analogs & derivatives; Proline - therapeutic use; Ribavirin - therapeutic use; United States; United States